SIDE EFFECTS
Rocephin is generally well tolerated. In clinical trials, the following adverse reactions, which were considered to be related to Rocephin therapy or of uncertain etiology, were observed:
Local Reactions: pain, induration and tenderness was 1% overall. Phlebitis was reported in <11% after IV administration. The incidence of injection site reaction was 17% (3/17) after IV administration of 350 mg/mL and 5% (1/20) after IM administration of 250 mg/mL.
Hypersensitivity: rash (1.7%). Less frequently reported (<1%) were pruritus, fever or chills.
Hematologic: eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%). Less frequently reported (<1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time.
Gastrointestinal: diarrhea (2.7%). Less frequently reported (<1%) were nausea or vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).
Hepatc: elevations of SGOT (3.1%) or SGPT (3.3%). Less frequently reported (<1%) were elevations of alkaline phosphatase and bilirubin.
Renal: elevations of the BUN (1.2%). Less frequently reported (<1%) were elevations of creatinine and the presence of casts in the urine.
Central Nervous System: headache or dizziness were reported occasionally (<1%).
Genitourinary: moniliasis or vaginitis were reported occasionally (<1%).
Miscellaneous: diaphoresis and flushing were reported occasionally (<1%).
Other rarely observed adverse reactions (<0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness.
DRUG INTERACTIONS
No information provided.
